Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): a post-hoc analysis of randomised controlled phase 3 trial
Open Access
- 1 March 2017
- journal article
- research article
- Published by Elsevier in The Lancet Oncology
- Vol. 18 (3) , 347-356
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Role of Positron Emission Tomography-Computed Tomography in the Management of Anal CancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2012
- Induction Chemotherapy and Dose Intensification of the Radiation Boost in Locally Advanced Anal Canal Carcinoma: Final Analysis of the Randomized UNICANCER ACCORD 03 TrialJournal of Clinical Oncology, 2012
- Concurrent cisplatin, continuous infusion fluorouracil and radiotherapy followed by tailored consolidation treatment in non metastatic anal squamous cell carcinomaBMC Cancer, 2011
- Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I)British Journal of Cancer, 2010
- Results of Surgical Salvage after Failed Chemoradiation Therapy for Epidermoid Carcinoma of the Anal CanalAnnals of Surgical Oncology, 2006
- Salvage abdominoperineal resection in anal epidermoid cancerBritish Journal of Surgery, 2002
- Anal Carcinoma: Prognostic Value of Endorectal Ultrasound (ERUS). Results of a Prospective Multicenter StudyEndoscopy, 2001
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000
- Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycinThe Lancet, 1996
- Chemoradiotherapy of Anal Carcinoma: Tumour Response and Acute ToxicityOncology, 1993